UB Paderborn / Katalog / Suche / in CDI

Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton’s Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases

Journal of medicinal chemistry, 2019-09, Vol.62 (17), p.7643-7655

2019

Volltextzugriff (PDF)

Ocular Distribution and Pharmacodynamics of SF0166, a Topically Administered α v β 3 Integrin Antagonist, for the Treatment of Retinal Diseases

The Journal of pharmacology and experimental therapeutics, 2018-08, Vol.366 (2), p.244-250

2018

Volltextzugriff (PDF)

11β-Hydroxysteroid dehydrogenase-1 as a therapeutic target for metabolic diseases

Expert opinion on therapeutic patents, 2005-03, Vol.15 (3), p.289-303

2005

Volltextzugriff (PDF)

Nonpeptide α vβ 3 antagonists. Part 9: Improved pharmacokinetic profile through the use of an aliphatic, des-amide backbone

Bioorganic & medicinal chemistry letters, 2004-09, Vol.14 (17), p.4411-4415

2004

Volltextzugriff (PDF)

Non-peptide αvβ3 antagonists. Part 3: Identification of potent RGD mimetics incorporating novel β-amino acids as aspartic acid replacements

Bioorganic & medicinal chemistry letters, 2002-01, Vol.12 (1), p.31-34

2002

Volltextzugriff (PDF)

Nonpeptide αvβ3 antagonists. Part 9: Improved pharmacokinetic profile through the use of an aliphatic, des-amide backbone

Bioorganic & medicinal chemistry letters, 2004-09, Vol.14 (17), p.4411-4415

2004

Volltextzugriff (PDF)

Nonpeptide αvβ3 Antagonists. Part 11: Discovery and Preclinical Evaluation of Potent αvβ3 Antagonists for the Prevention and Treatment of Osteoporosis

Journal of medicinal chemistry, 2004-09, Vol.47 (20), p.4829-4837

2004

Volltextzugriff (PDF)

Nonpeptide glycoprotein IIb/IIIa inhibitors. 15. Antithrombotic efficacy of L-738,167, a long-acting GPIIb/IIIa antagonist, correlates with inhibition of adenosine diphosphate-induced platelet aggregation but not with bleeding time prolongation

The Journal of pharmacology and experimental therapeutics, 1997-05, Vol.281 (2), p.677

1997

Volltextzugriff (PDF)

Nonpeptide GPIIB/IIIA receptor antagonists. Part 21: C-6 flexibility and amide bond orientation are important factors in determining the affinity of compounds for activated or resting platelet receptors

Bioorganic & medicinal chemistry letters, 2000-09, Vol.10 (17), p.1943-1948

2000

Volltextzugriff (PDF)

Non-peptide alpha(v)beta(3) antagonists. Part 4: potent and orally bioavailable chain-shortened RGD mimetics

Bioorganic & medicinal chemistry letters, 2002-09, Vol.12 (17), p.2463

2002

Volltextzugriff (PDF)

Non-Peptide αvβ3 Antagonists. Part 4: Potent and Orally Bioavailable Chain-Shortened RGD Mimetics

Bioorganic & medicinal chemistry letters, 2002-09, Vol.12 (17), p.2463-2465

2002

Volltextzugriff (PDF)

Non-Peptide α vβ 3 antagonists. Part 3: Identification of potent RGD mimetics incorporating novel β-Amino acids as aspartic acid replacements

Bioorganic & medicinal chemistry letters, 2002-01, Vol.12 (1), p.31-34

2002

Volltextzugriff (PDF)

Nonpeptide alphavbeta3 antagonists. Part 11: discovery and preclinical evaluation of potent alphavbeta3 antagonists for the prevention and treatment of osteoporosis

Journal of medicinal chemistry, 2004-09, Vol.47 (20), p.4829

2004

Volltextzugriff (PDF)

Nonpeptide α v β 3 Antagonists. Part 11: Discovery and Preclinical Evaluation of Potent α v β 3 Antagonists for the Prevention and Treatment of Osteoporosis

Journal of medicinal chemistry, 2004-09, Vol.47 (20), p.4829-4837

2004

Volltextzugriff (PDF)

Disposition of L-738,167, a potent and long-acting fibrinogen receptor antagonist, in dogs. Dose-dependent pharmacokinetics

Drug metabolism and disposition, 1997-03, Vol.25 (3), p.355

1997

Volltextzugriff (PDF)

Non-peptide alpha(v)beta(3) antagonists. Part 3: identification of potent RGD mimetics incorporating novel beta-amino acids as aspartic acid replacements

Bioorganic & medicinal chemistry letters, 2002-01, Vol.12 (1), p.31

2002

Volltextzugriff (PDF)

Non-Peptide α vβ 3 Antagonists. Part 4: Potent and Orally Bioavailable Chain-Shortened RGD Mimetics

Bioorganic & medicinal chemistry letters, 2002, Vol.12 (17), p.2463-2465

2002

Volltextzugriff (PDF)

Non-peptide αvβ3 antagonists. Part 4: Potent and orally bioavailable chain-shortened TGD mimetics

Bioorganic & medicinal chemistry letters, 2002, Vol.12 (17), p.2463-2465

2002

Volltextzugriff (PDF)

Nonpeptide glycoprotein IIb/IIIa inhibitors 14 : Oral antithrombotic efficacy of L-738,167 in a conscious canine model of coronary artery electrolytic injury

Circulation (New York, N.Y.), 1997-08, Vol.96 (3), p.949-958

1997

Volltextzugriff (PDF)

Species and organ differences in first-pass metabolism of the ester prodrug L-751,164 in dogs and monkeys. In vivo and in vitro studies

Drug metabolism and disposition, 1996-11, Vol.24 (11), p.1263

1996

Volltextzugriff (PDF)

Non-peptide fibrinogen receptor antagonists. 2. The synthesis of [3H]L-738,167

Journal of labelled compounds & radiopharmaceuticals, 1998-04, Vol.41 (4), p.273-277

1998

Volltextzugriff (PDF)

Non-peptide fibrinogen receptor antagonists. 21. The synthesis of [3H]L-738,167

Journal of labelled compounds & radiopharmaceuticals, 1998-04, Vol.41 (4), p.273-277

1998

Volltextzugriff (PDF)

Community-level impact of the reproductive health vouchers programme on service utilization in Kenya

Health policy and planning, 2013-03, Vol.28 (2), p.165-175

2013

Volltextzugriff (PDF)

Molecular recognition: Watson-Crick, Hoogsteen, and bifurcated hydrogen bonding in a model for adenine recognition

Journal of the American Chemical Society, 1987-10, Vol.109 (22), p.6866-6867

1987

Volltextzugriff (PDF)

Molecular recognition with convergent functional groups. VII. Energetics of adenine binding with model receptors

Journal of the American Chemical Society, 1989-02, Vol.111 (3), p.1090-1094

1989

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton’s Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases

Ocular Distribution and Pharmacodynamics of SF0166, a Topically Administered α v β 3 Integrin Antagonist, for the Treatment of Retinal Diseases

11β-Hydroxysteroid dehydrogenase-1 as a therapeutic target for metabolic diseases

Nonpeptide α vβ 3 antagonists. Part 9: Improved pharmacokinetic profile through the use of an aliphatic, des-amide backbone

Non-peptide αvβ3 antagonists. Part 3: Identification of potent RGD mimetics incorporating novel β-amino acids as aspartic acid replacements

Nonpeptide αvβ3 antagonists. Part 9: Improved pharmacokinetic profile through the use of an aliphatic, des-amide backbone

Nonpeptide αvβ3 Antagonists. Part 11: Discovery and Preclinical Evaluation of Potent αvβ3 Antagonists for the Prevention and Treatment of Osteoporosis

Nonpeptide glycoprotein IIb/IIIa inhibitors. 15. Antithrombotic efficacy of L-738,167, a long-acting GPIIb/IIIa antagonist, correlates with inhibition of adenosine diphosphate-induced platelet aggregation but not with bleeding time prolongation

Nonpeptide GPIIB/IIIA receptor antagonists. Part 21: C-6 flexibility and amide bond orientation are important factors in determining the affinity of compounds for activated or resting platelet receptors

Non-peptide alpha(v)beta(3) antagonists. Part 4: potent and orally bioavailable chain-shortened RGD mimetics

Non-Peptide αvβ3 Antagonists. Part 4: Potent and Orally Bioavailable Chain-Shortened RGD Mimetics

Non-Peptide α vβ 3 antagonists. Part 3: Identification of potent RGD mimetics incorporating novel β-Amino acids as aspartic acid replacements

Nonpeptide alphavbeta3 antagonists. Part 11: discovery and preclinical evaluation of potent alphavbeta3 antagonists for the prevention and treatment of osteoporosis

Nonpeptide α v β 3 Antagonists. Part 11: Discovery and Preclinical Evaluation of Potent α v β 3 Antagonists for the Prevention and Treatment of Osteoporosis

Disposition of L-738,167, a potent and long-acting fibrinogen receptor antagonist, in dogs. Dose-dependent pharmacokinetics

Non-peptide alpha(v)beta(3) antagonists. Part 3: identification of potent RGD mimetics incorporating novel beta-amino acids as aspartic acid replacements

Non-Peptide α vβ 3 Antagonists. Part 4: Potent and Orally Bioavailable Chain-Shortened RGD Mimetics

Non-peptide αvβ3 antagonists. Part 4: Potent and orally bioavailable chain-shortened TGD mimetics

Nonpeptide glycoprotein IIb/IIIa inhibitors 14 : Oral antithrombotic efficacy of L-738,167 in a conscious canine model of coronary artery electrolytic injury

Species and organ differences in first-pass metabolism of the ester prodrug L-751,164 in dogs and monkeys. In vivo and in vitro studies

Non-peptide fibrinogen receptor antagonists. 2. The synthesis of [3H]L-738,167

Non-peptide fibrinogen receptor antagonists. 21. The synthesis of [3H]L-738,167

Community-level impact of the reproductive health vouchers programme on service utilization in Kenya

Molecular recognition: Watson-Crick, Hoogsteen, and bifurcated hydrogen bonding in a model for adenine recognition

Molecular recognition with convergent functional groups. VII. Energetics of adenine binding with model receptors

Suchergebnisse filtern